Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?
- 18 November 2009
- journal article
- research article
- Published by Springer Nature in Journal of Business Ethics
- Vol. 94 (2) , 225-242
- https://doi.org/10.1007/s10551-009-0259-x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Does orphan drug legislation really answer the needs of patients?The Lancet, 2008
- New uses for old drugsNature, 2007
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- Ethical issues in funding orphan drug research and developmentJournal of Medical Ethics, 2005
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- The Orphan Drug BacklashScientific American, 2003
- Priceless Goods: How Should Life-Saving Drugs be Priced?Business Ethics Quarterly, 2002
- Corporate Social ResponsibilityBusiness & Society, 1999
- Towards the Sustainable Corporation: Win-Win-Win Business Strategies for Sustainable DevelopmentCalifornia Management Review, 1994
- Rivalry, strategic groups and firm profitabilityStrategic Management Journal, 1993